<DOC>
	<DOCNO>NCT00238615</DOCNO>
	<brief_summary>The purpose study assess well particular combination chemotherapy , radiation surgery work help people locally advanced lung cancer , well PET scan indicate whether someone respond chemotherapy radiation , gene expression pattern relate outcome patient locally advanced lung cancer receive treatment regimen .</brief_summary>
	<brief_title>Phase II Docetaxel / Carboplatin / XRT + Surgical Resection Stage III NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm stage IIIA IIIB NSCLC Patients must measurable disease No previous chemotherapy , radiation therapy systemic therapy NSCLC . Age &gt; 18 year Life expectancy &gt; 12 month ECOG performance status 01 Normal organ marrow function Medically fit surgery time enrollment . Women childbearing potential men must agree use adequate contraception prior study entry duration study . Women must negative pregnancy test prior enrollment . Ability understand willingness sign consent form . Previous chemotherapy , radiation therapy systemic treatment NSCLC . Patients receive investigational agent . Known metastatic disease ( brain site ) History severe hypersensitivity reaction docetaxel drug formulate polysorbate 80 allergic reaction compound similar chemical composition carboplatin agent use study . Peripheral neuropathy &gt; grade 1 Uncontrolled concurrent illness Pregnant woman Weight loss &gt; 10 % past 3 month diagnosis . Hyperglycemia exclusion PET analysis HIV positive patient receive combination antiretroviral therapy possible pharmacokinetic interaction docetaxel carboplatin agent administer study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>